Curevac publishes in nature preclinical data of second-generation covid-19 candidate, cv2cov, demonstrating comparable antibody levels to licensed mrna vaccine

TÜbingen, germany / boston, ma / accesswire / november 18, 2021 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced the online publication of the extended preclinical study of the second-generation vaccine candidate, cv2cov, jointly developed with gsk, in the journal nature.
CVAC Ratings Summary
CVAC Quant Ranking